Rahika 150mg

Rahika 150mg is a prescription medication used to treat certain types of cancer, including non-small cell lung cancer (NSCLC). It is a MET inhibitor that works by inhibiting the growth of cancer cells and reducing the production of new blood vessels that feed the tumor.

Composition:

• Rahika 150mg: Capmatinib 150mg

Mechanism of Action:

Capmatinib, the active ingredient in Rahika, is a MET inhibitor that works by:

1. Inhibiting the growth of cancer cells by blocking the action of specific enzymes that promote cell growth and division.
2. Reducing the production of new blood vessels that feed the tumor, which helps to reduce its growth and spread.
3. Inhibiting the activity of various signaling pathways that contribute to cancer cell growth and survival.

Indications:

Rahika is approved for the treatment of:

1. Non-small cell lung cancer (NSCLC) in patients who have progressed after previous treatment and have tumors with a MET exon 14 skipping mutation.

Dosage:

The recommended dosage of Rahika is:

• 150mg orally twice daily, taken at the same time every day.
• The recommended duration of treatment is until disease progression or unacceptable toxicity.

Side Effects:

Common side effects of Rahika include:

1. Nausea
2. Fatigue
3. Diarrhea
4. Abdominal pain
5. Headache
6. Skin rash
7. Hair loss
8. Muscle pain
9. Increased risk of bleeding or bruising
10. Increased risk of liver enzyme elevation

Recommendation:

Rahika is recommended for patients who have been diagnosed with NSCLC and have a MET exon 14 skipping mutation and have not responded to other treatments or have disease that has progressed after surgery and radiation therapy.

Important Note:

• Patients taking Rahika should be closely monitored for signs of bleeding or bruising due to the risk of thrombocytopenia.
• Patients taking Rahika should avoid taking medications that may increase the risk of bleeding or bruising.
• Pregnant or breastfeeding women should not use Rahika, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Rahika and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of kidney disease should be closely monitored for signs of worsening kidney function while taking Rahika.
• Patients taking Rahika should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase blood pressure.
• Patients with a history of heart disease or high blood pressure should be closely monitored while taking Rahika.

Contraindications:

• Patients with severe liver disease or severe kidney disease should not use Rahika.
• Patients who are allergic to capmatinib or any other component of Rahika should not use it.
• Patients who are pregnant or breastfeeding should not use Rahika.